[1] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1):7-33.
[2] SULHEIM E, KIM J, VAN WAMEL A, et al. Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models. J Controlled Release, 2018, 279:292-305.
[3] SORRIN A J, KEMAL RUHI M, FERLIC N A, et al. Photodynamic therapy and the biophysics of the tumor microenvironment. Photochem Photobiol, 2020, 96(2):232-259.
[4] HONG J Y. Study on the anti-tumor synergistic effect of Panlisin nano-targeted preparation. Beijing:Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, 2017.
[5] MAEDA H, WU J, SAWA T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics:a review. J Controlled Release, 2000, 65(1-2):271-284.
[6] SINDHWANI S, SYED A M, NGAI J, et al. The entry of nanoparticles into solid tumours. Nat Mater, 2020, 19(5):566-575.
[7] TAN J, XIE Z L, SU Y Q, et al. Preparation of multifunctional chimeric peptide T7-R8/DNA nanocomplexes and evaluation of inhibiting melanoma cells in vitro. Chin Pharm J (中国药学杂志), 2021, 56(2):122-127.
[8] MATSUMURA Y, MAEDA H. A new concept for macromolecular therapeutics in cancer chemotherapy:mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 1986, 46(12 Pt 1):6387-6392.
[9] GERMAIN M, CAPUTO F, METCALFE S, et al. Delivering the power of nanomedicine to patients today. J Controlled Release, 2020, 326:164-171.
[10] ZI Y, YANG K, HE J, et al. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev, 2022, 188:114449. Doi: 10.1016/j.addr.2022.114449.
[11] VENDITTO V J, SZOKA F C, J R. Cancer nanomedicines:so many papers and so few drugs!. Adv Drug Deliv Rev, 2013, 65(1):80-88.
[12] JAIN R K. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy. Science, 2005, 307(5706):58-62.
[13] JACOBETZ M A, CHAN D S, NEESSE A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 2013, 62(1):112-120.
[14] DALY H C, CONROY E, TODOR M, et al. An EPR Strategy for Bio-responsive Fluorescence Guided Surgery with Simulation of the Benefit for Imaging. Theranostics, 2020, 10(7):3064-3082.
[15] HE Z, YAN H, ZENG W, et al. Tumor microenvironment-responsive multifunctional nanoplatform based on MnFe(2)O(4)-PEG for enhanced magnetic resonance imaging-guided hypoxic cancer radiotherapy. J Mater Chem B, 2021, 9(6):1625-1637.
[16] LIU S, LI W, GAI S, et al. A smart tumor microenvironment responsive nanoplatform based on upconversion nanoparticles for efficient multimodal imaging guided therapy. Biomater Sci, 2019, 7(3):951-962.
[17] GOLOMBEK S K, MAY J N, THEEK B, et al. Tumor targeting via EPR:Strategies to enhance patient responses. Adv Drug Deliv Rev, 2018, 130:17-38. Doi: 10.1016/j.addr.2018.07.007.
[18] ISLAM R, MAEDA H, FANG J. Factors affecting the dynamics and heterogeneity of the EPR effect:pathophysiological and pathoanatomic features, drug formulations and physicochemical factors. Expert Opin Drug Deliv, 2022, 19(2):199-212.
[19] HUANG J, ZOU J N, REN H H, et al. Novel strategies for promoting tumor penetration of anticancer nanomedicines.. Acta Pharm Sin(药学学报), 2022, 57(6):1758-1770.
[20] SUN X, YAN X, JACOBSON O, et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics, 2017, 7(2):319-328.
[21] TSOI K M, MACPARLAND S A, MA X Z, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater, 2016, 15(11):1212-1221.
[22] KANG H, RHO S, STILES W R, et al. Size-Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting. Adv Healthc Mater, 2020, 9(1):e1901223. Doi: 10.1002/adhm.201901223.
[23] DREHER M R, LIU W, MICHELICH C R, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst, 2006, 98(5):335-344.
[24] PASTORE C. Size-dependent nano-bio interactions. Nat Nanotechnol, 2021, 16(10):1052. Doi: 10.1038/s41565-021-00996-z.
[25] PATTIPEILUHU R, ARIAS-ALPIZAR G, BASHA G, et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. Adv Mater, 2022, 34(16):e2201095. Doi: 10.1038/s41565-021-00996-z.
[26] YANG Z Z, LI J Q, WANG Z Z, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials, 2014, 35(19):5226-5239.
[27] ZHOU Y, LIU R, SHEVTSOV M, et al. When imaging meets size-transformable nanosystems. Adv Drug Deliv Rev, 2022, 183:114176. Doi: 10.1016/j.addr.2022.114176.
[28] CHENG X, LI H, GE X, et al. Tumor-microenvironment-responsive size-shrinkable drug-delivery nanosystems for deepened penetration into tumors. Front Mol Biosci, 2020, 7:576420. Doi: 10.3389/fmolb.2020.576420.
[29] DAS R P, GANDHI V V, SINGH B G, et al. Passive and active drug targeting:role of nanocarriers in rational design of anticancer formulations. Curr Pharm Des, 2019, 25(28):3034-3056.
[30] GOU J, LIANG Y, MIAO L, et al. Improved tumor tissue penetration and tumor cell uptake achieved by delayed charge reversal nanoparticles. Acta Biomater, 2017, 62:157-166.
[31] NATFJI A A, RAVISHANKAR D, OSBORN H M I, et al. Parameters affecting the enhanced permeability and retention effect:the need for patient selection. J Pharm Sci, 2017, 106(11):3179-3187.
[32] ANDERSON H, YAP J T, WELLS P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer, 2003, 89(2):262-267.
[33] MATTHEOLABAKIS G, MIKELIS C M. Nanoparticle delivery and tumor vascular normalization:the chicken or the Egg?. Front Oncol, 2019, 9:1227. Doi: 10.3389/fonc.2019.01227.
[34] MAEDA H, FANG J, INUTSUKA T, et al. Vascular permeability enhancement in solid tumor:various factors, mechanisms involved and its implications. Int Immunopharmacol, 2003, 3(3):319-328.
[35] LIU Y, LI Y, XUE G, et al. Shape switching of CaCO₃-templated nanorods into stiffness-adjustable nanocapsules to promote efficient drug delivery. Acta Biomater, 2021, 128:474-485.
[36] SOANS K G, NORDEN C. Shining a light on extracellular matrix dynamics in vivo. Semin Cell Dev Biol, 2021, 120:85-93. Doi: 10.1016/j.semcdb.2021.05.008.
[37] ZHAO Y, CAO J, MELAMED A, et al. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A, 2019, 116(6):2210-2219.
[38] VAUPEL P, MAYER A, HÖCKEL M. Tumor hypoxia and malignant progression. Methods Enzymol, 2004, 381:335-354.
[39] CHEN X, ZHANG X, ZHANG L, et al. An EPR-independent therapeutic strategy: Cancer cell-mediated dual-drug delivery depot for diagnostics and prevention of hepatocellular carcinoma metastasis . Biomaterials, 2021, 268: 120541. DOI:10.1016/j.biomaterials.2020.120541
[40] LI X, ZHU D D, CHEN Y, et al. Progress in deep tumor penetration by nanoparticle-based drug delivery system in cancer therapy. Cent South Pharm(中南药学), 2020, 18(12):2009-2018.
[41] CABRAL H, MATSUMOTO Y, MIZUNO K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol, 2011, 6(12):815-823.
[42] DADPOUR S, MEHRABIAN A, ARABSALMANI M, et al. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity. IET Nanobiotechnol, 2022, 16(7-8):259-272.
[43] ZHANG L, WANG Y, YANG D, et al. Shape effect of nanoparticles on tumor penetration in monolayers versus spheroids. Mol Pharm, 2019, 16(7):2902-2911.
[44] WANG Y, BLACK K C, LUEHMANN H, et al. Comparison study of gold nanohexapods, nanorods, and nanocages for photothermal cancer treatment. ACS Nano, 2013, 7(3):2068-2077.
[45] GUO Y, WANG T, ZHAO S, et al. Amphiphilic hybrid dendritic-linear molecules as nanocarriers for shape-dependent antitumor drug delivery. Mol Pharm, 2018, 15(7):2665-2673.
[46] CHEN D, GANESH S, WANG W, et al. Plasma protein adsorption and biological identity of systemically administered nanoparticles. Nanomedicine (Lond), 2017, 12(17):2113-2135.
[47] CAMPBELL F, BOS F L, SIEBER S, et al. Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake. ACS Nano, 2018, 12(3):2138-2150.
[48] HUANG K, BOERHAN R, LIU C, et al. Nanoparticles penetrate into the multicellular spheroid-on-chip:effect of surface charge, protein corona, and exterior flow. Mol Pharm, 2017, 14(12):4618-4627.
[49] IKEDA-IMAFUKU M, WANG L L, RODRIGUES D, et al. Strategies to improve the EPR effect:a mechanistic perspective and clinical translation. J Controlled Release, 2022, 345:512-536. Doi: 10.1073/pnas.1411499111.
[50] TANG L, YANG X, YIN Q, et al. Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci USA, 2014, 111(43):15344-15349.
[51] WANG K W. Size-switchable polymeric nanocarriers for hypoxic-tumor therapy. Guangzhou:South China University of Technology, 2021.
[52] YE D, SHUHENDLER A J, CUI L, et al. Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat Chem, 2014, 6(6):519-526.
[53] XIONG H, WANG Z, WANG C, et al. Transforming complexity to simplicity:protein-like nanotransformer for improving tumor drug delivery programmatically. Nano Lett, 2020, 20(3):1781-1790.
[54] YE W, CHEN X, LI X, et al. Structure-switchable DNA programmed disassembly of nanoparticles for smart size tunability and cancer-specific drug release. ACS Appl Mater Interfaces, 2020, 12(20):22560-22571.
[55] SMITH B R, KEMPEN P, BOULEY D, et al. Shape matters:intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett, 2012, 12(7):3369-3377.
[56] LI Y, KRÖGER M, LIU W K. Shape effect in cellular uptake of PEGylated nanoparticles:comparison between sphere, rod, cube and disk. Nanoscale, 2015, 7(40):16631-16646.
[57] MA N, WU F G, ZHANG X, et al. Shape-dependent radiosensitization effect of gold nanostructures in cancer radiotherapy:comparison of gold nanoparticles, nanospikes, and nanorods. ACS Appl Mater Interfaces, 2017, 9(15):13037-13048.
[58] TAHMASBI RAD A, CHEN C-W, ARESH W, et al. Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers. ACS Appl Mater Interfaces, 2019, 11(11):10505-10519.
[59] WANG Z, WANG Y, JIA X, et al. MMP-2-Controlled transforming micelles for heterogeneic targeting and programmable cancer therapy. Theranostics, 2019, 9(6):1728-1740.
[60] GAN Z J,PEI J B. Enzyme-responsive nanoparticles in tumor therapy: superiority of nanoparticles inaccumulation and drug release. Chin J Tissue Eng Res(中国组织工程研究),2021,25(16):2562-2568.
[61] ZHANG M, CHEN X, LI C, et al. Charge-reversal nanocarriers:an emerging paradigm for smart cancer nanomedicine. J Controlled Release, 2020, 319:46-62.
[62] WANG S, ZHANG F, YU G, et al. Zwitterionic-to-cationic charge conversion polyprodrug nanomedicine for enhanced drug delivery. Theranostics, 2020, 10(15):6629-6637.
[63] SONG H, XING W, SHI X, et al. Antitumor and toxicity study of mitochondria-targeted triptolide derivatives using triphenylphosphine (TPP(+)) as a carrier. Bioorg Med Chem, 2021, 50:116466. Doi: 10.1016/j.bmc.2021.116466.
[64] YU H, LI J M, DENG K, et al. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy. Theranostics, 2019, 9(23):7033-7050.
[65] WAN M M, CHEN H, DA WANG Z, et al. Nitric oxide-driven nanomotor for deep tissue penetration and multidrug resistance reversal in cancer therapy. Adv Sci (Weinh), 2021, 8(3):2002525. Doi: 10.1002/advs.202002525.
[66] ISLAM W, FANG J, IMAMURA T, et al. Augmentation of the enhanced permeability and retention effect with nitric oxide-generating agents improves the therapeutic effects of nanomedicines. Mol Cancer Ther, 2018, 17(12):2643-2653.
[67] SU B, CENGIZEROGLU A, FARKASOVA K, et al. Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer. Mol Ther, 2013, 21(2):300-308.
[68] LUO L, LIU S, ZHANG D, et al. Chromogranin A (CGA)-derived polypeptide (CGA47-66) inhibits TNF-α-induced vascular endothelial hyper-permeability through SOC-related Ca²⁺ signaling. Peptides, 2020, 131:170297. Doi: 10.1016/j.peptides.2020.170297.
[69] NAGAHARA R, ONDA N, YAMASHITA S, et al. Fluorescence tumor imaging by i.v. administered indocyanine green in a mouse model of colitis-associated colon cancer. Cancer Sci, 2018, 109(5):1638-1647.
[70] MAEDA H, NAKAMURA H, FANG J. The EPR effect for macromolecular drug delivery to solid tumors:improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev, 2013, 65(1):71-79.
[71] TUTEJA N, CHANDRA M, TUTEJA R, et al. Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J Biomed Biotechnol, 2004, 2004(4):227-237.
[72] ALIMORADI H, GREISH K, GAMBLE A B, et al. Controlled delivery of nitric oxide for cancer therapy. Pharm Nanotechnol, 2019, 7(4):279-303.
[73] DONG X, LIU H J, FENG H Y, et al. Enhanced drug delivery by nanoscale integration of a nitric oxide donor to induce tumor collagen depletion. Nano Lett, 2019, 19(2):997-1008.
[74] SHI M, ZHANG J, WANG Y, et al. Tumor-specific nitric oxide generator to amplify peroxynitrite based on highly penetrable nanoparticles for metastasis inhibition and enhanced cancer therapy. Biomaterials, 2022, 283:121448. Doi: 10.1016/j.biomaterials.2022.121448.
[75] HOFMANN S, GRASBERGER H, JUNG P, et al. The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Eur J Med Res, 2002, 7(4):171-176.
[76] MURATA T, LIN M I, ARITAKE K, et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci USA, 2008, 105(50): 20009-20014.
[77] HUANG D, SUN L, HUANG L, et al. Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. J Pers Med, 2021, 11(2):124. Doi: 10.3390/jpm11020124.
[78] TANAKA S, AKAIKE T, WU J, et al. Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. J Drug Target, 2003, 11(1):45-52.
[79] LIU Y, HASHIZUME K, CHEN Z, et al. Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res, 2001, 23(4):379-387.
[80] BAZZI Z A, BALUN J, CAVALLO-MEDVED D, et al. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells:potential relevance to the breast tumour microenvironment. Clin Exp Metastasis, 2017, 34(2):155-169.
[81] MELINCOVICI C S, BOşCA A B,şUşMAN S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol, 2018, 59(2):455-467.
[82] ZHANG B, JIANG T, TUO Y, et al. Captopril improves tumor nanomedicine delivery by increasing tumor blood perfusion and enlarging endothelial gaps in tumor blood vessels. Cancer Lett, 2017, 410:12-19.
[83] WAHYUDI H, REYNOLDS A A, LI Y, et al. Targeting collagen for diagnostic imaging and therapeutic delivery. J Controlled Release, 2016, 240:323-331.
[84] ZINGER A, KOREN L, ADIR O, et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano, 2019, 13(10):11008-11021.
[85] CHEN E, HAN S, SONG B, et al. Mechanism investigation of hyaluronidase-combined multistage nanoparticles for solid tumor penetration and antitumor effect. Int J Nanomed, 2020, 15:6311-6324.
[86] BREKKEN C, DE LANGE DAVIES C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett, 1998, 131(1):65-70.
[87] SEKI T, SAIDA Y, KISHIMOTO S, et al. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia, 2022, 30:100793. Doi: 10.1016/j.neo.2022.100793.
[88] MOROSI L, MERONI M, UBEZIO P, et al. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. J Exp Clin Cancer Res, 2021, 40(1):286. Doi: 10.1186/s13046-021-02070-x.
[89] LIU P, WANG Y, LIU Y, et al. S-nitrosothiols loaded mini-sized Au@silica nanorod elicits collagen depletion and mitochondrial damage in solid tumor treatment. Theranostics, 2020, 10(15):6774-6789.
[90] FU Y, SARASWAT A L, MONPARA J, et al. Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor . Drug Discov Today, 2022, 27(4): 1132-1141.
[91] YOSHIDA E, KUDO D, NAGASE H, et al. 4-Methylumbelliferone decreases the hyaluronan-rich extracellular matrix and increases the effectiveness of 5-fluorouracil. Anticancer Res, 2018, 38(10):5799-5804.
[92] SUTO A, KUDO D, YOSHIDA E, et al. Increase of tumor infiltrating γδ T-cells in pancreatic ductal adenocarcinoma through remodeling of the extracellular matrix by a hyaluronan synthesis suppressor, 4-methylumbelliferone. Pancreas, 2019, 48(2):292-298.
[93] CHEN Y, LIU X, YUAN H, et al. Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery. Adv Sci (Weinh), 2019, 6(5):1802070. Doi: 10.1002/advs.201802070.
[94] LI Y, ZHAO Z, LIU H, et al. Development of a tumor-responsive nanopolyplex targeting pancreatic cancer cells and stroma. ACS Appl Mater Interfaces, 2019, 11(49):45390-45403.
[95] CARIGGA GUTIERREZ N M, PUJOL-SOLÉN, ARIFI Q, et al. Increasing cancer permeability by photodynamic priming:from microenvironment to mechanotransduction signaling. Cancer Metastasis Rev, 2022, 41(4): 899-934.
[96] HATFIELD S M, KJAERGAARD J, LUKASHEV D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med, 2015, 7(277):277ra230. Doi:10.1126/scitranslmed.aaa1260.
[97] CAVIN S, RIEDEL T, ROSSKOPFOVA P, et al. Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility. Laser Surg Med, 2019, 51(6):550-561.
[98] OVERCHUK M, HARMATYS K M, SINDHWANI S, et al. Subtherapeutic photodynamic treatment facilitates tumor nanomedicine delivery and overcomes desmoplasia. Nano Lett, 2021, 21(1):344-352.
[99] DUNNE M, REGENOLD M, ALLEN C. Hyperthermia can alter tumor physiology and improve chemo-and radio-therapy efficacy. Adv Drug Deliv Rev, 2020, 163-164:98-124.
[100] SEYNHAEVE A L B, AMIN M, HAEMMERICH D, et al. Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv Drug Deliv Rev, 2020, 163-164:125-144.
[101] HAEMMERICH D, MOTAMARRY A. Thermosensitive liposomes for image-guided drug delivery. Adv Cancer Res, 2018, 139:121-146.
[102] ZHU M X. Tumor microenvironment-responsive polydopamine nanomotors for synergistictumor therapy. Hangzhou:Zhe Jiang University, 2022.
[103] GAO Y, HUANG W, YANG C, et al. Targeted photothermal therapy of mice and rabbits realized by macrophage-loaded tungsten carbide. Biomater Sci, 2019, 7(12):5350-5358.
[104] ZUO C, ZOU Y, GAO G, et al. Photothermal combined with intratumoral injection of annonaceous acetogenin nanoparticles for breast cancer therapy. Colloids Surf B Biointerfaces, 2022, 213:112426. Doi: 10.1016/j.colsurfb.2022.112426. 104.
[105] HUA S, HE J, ZHANG F, et al. Multistage-responsive clustered nanosystem to improve tumor accumulation and penetration for photothermal/enhanced radiation synergistic therapy. Biomaterials, 2021, 268:120590. Doi:10.1016/j.biomaterials.2020.120590.
[106] THEEK B, BAUES M, OJHA T, et al. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J Controlled Release, 2016, 231:77-85.
[107] OJHA T, PATHAK V, SHI Y, et al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev, 2017, 119:44-60.
[108] CAO Y, CHEN Y, YU T, et al. Drug release from phase-changeable nanodroplets triggered by Low-Intensity Focused Ultrasound. Theranostics, 2018, 8(5):1327-1339.
[109] DUAN L, YANG L, JIN J, et al. Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications. Theranostics, 2020, 10(2):462-483.
[110] WU H, LI W, HAO M, et al. An EPR-Independent extravasation strategy:deformable leukocytes as vehicles for improved solid tumor therapy. Adv Drug Deliv Rev, 2022, 187:114380. Doi: 10.1016/j.addr.2022.114380.
[111] MANTOVANI A, MARCHESI F, JAILLON S, et al. Tumor-associated myeloid cells:diversity and therapeutic targeting. Cell Mol Immunol, 2021, 18(3):566-578.
[112] MULLER W A. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol, 2003, 24(6):327-334.
[113] ZHOU Q, DONG C, FAN W, et al. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy:the current status and transcytosis strategy. Biomaterials, 2020, 240:119902. Doi: 10.1016/j.biomaterials.2020.119902.
[114] MORENO V M, BAEZA A. Bacteria as nanoparticle carriers for immunotherapy in oncology. Pharmaceutics, 2022,14(4):784. Doi: 10.3390/pharmaceutics14040784.
[115] SWETHA K L, ROY A. Tumor heterogeneity and nanoparticle-mediated tumor targeting:the importance of delivery system personalization. Drug Deliv Transl Res, 2018, 8(5):1508-1526.
[116] GHAFOOR S, BURGER I A, VARGAS A H. Multimodality imaging of prostate cancer. J Nucl Med, 2019, 60(10):1350-1358.